Add a listing
0
Add a listing

Zymeworks, Jazz agree to licensing deal for cancer drug

zymeworks,-jazz-agree-to-licensing-deal-for-cancer-drug

Shares of Zymeworks Inc. ZYME, +9.00% gained 8.4% in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -1.95% for its cancer drug, zanidatamab, which is currently being tested as a treatment for some HER2-expressing cancers. Jazz will pay Zymeworks $50 million upfront. Including all regulatory and commercial milestone payments, the deal, which is expected to close before the end of the year, is worth up to a total $1.7 billion. Zymeworks’ stock is down 66.7% this year, while the S&P 500 SPX, -0.36% has declined 21.9%.

Source: Marketwatch

Related Posts

Recent Posts
Leading Key
Asian Shares Asian Stocks bafin Blog brent brokerswatch CBI Ireland cftc cointelegraph Commodities Crude Oil energy european fca fcnb FINRA Forex fsma fxpro Gold gold-price Inflation Interview Market Analysis markets Marketwatch News News stories oil oott OPEC Press Release Press Releases Roboforex Russia Speech Statements stock markets Stocks Technical analysis tickmill Trading Warning Notice wti xgloabalmarkets
About
brokerswatch white red logo
Searching for the right forex broker is no easy task, but have no fear! Brokerswatch.com has made it very simple.  Find the right brokers based on the criteria most important to you and compare them side by side for easier selection
Twitter Facebook-f Instagram Linkedin Reddit

Brokers By Regulator

Forex Brokers List

Trading Tools

Risk Warning: FX trading is high risk and may not be suitable for all investors. Leverage will create additional risks and loss. Before trading, please carefully consider your investment goals, experience and risk tolerance levels. Loss of  part or all of your initial investment is possible;  therefore do not invest money that you cannot afford to lose. It is advised to educate yourself about FX trading before you trade real money. Disclaimer:  All data and information on this Website are provided “as is” and to be used only for information purposes.  Information is not  intended for trading or trading recommendations.  The operators of this website shall not be liable for any loss incurred by you as a result of reliance on the information contained in the Website.